Clinical trial
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol)…
NCT00445458 · Puma Biotechnology, Inc., Industry · Completed
Key facts
| NCT number | NCT00445458 |
|---|---|
| Title | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer |
| Official title | A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer |
| Lead sponsor | Puma Biotechnology, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | HKI-272, Paclitaxel |
| Enrollment | 110 |
| Start date | Sep 11, 2007 |
| Primary completion | May 1, 2011 |
| Completion | Feb 7, 2018 |
| First posted | Mar 9, 2007 |
| Last update posted | Jul 26, 2018 |
| Countries | Belgium, Canada, China, Hong Kong, India, Poland, South Korea, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: